The Delhi High Court has permitted Zydus Lifesciences to produce and market a biosimilar cancer drug. This decision comes as the patent for the original drug, Nivolumab, nears its expiration. The court prioritized patient access to affordable treatment. Zydus can now proceed with its biosimilar, ZRC-3276, while maintaining sales records.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1xJoX3t
via IFTTT
No comments:
Post a Comment